A Phase 3 interventional study of Aliskiren 300 mg and Aliskiren/Amlodipine 300/5 mg in Hypertension, sponsored by Novartis. Completed at 9 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-07-12.
Sponsored by Novartis · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 228 studies in Hypertension by Novartis — 5 open to participants now, 6 under way, none of them phase 3. Hypertension · Novartis.
Among the 228 studies in Hypertension by Novartis, this one is the 45th largest by enrollment of the 223 interventional ones that give a count, is one of 25 that started in 2008, is one of 108 in phase 3, and was the 147th registered.
6,128 studies on the registry are indexed under Hypertension; 911 are open to participants now.
Browse Hypertension studies →5 of the 228 studies in Hypertension by Novartis are open now, in 4 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United Arab Emirates
Ages 18–99
Novartis Pharmaceuticals · Sites in Japan
Ages 18–60 · Healthy volunteers
Novartis Pharmaceuticals · Sites in United States
Ages 18–75
Novartis Pharmaceuticals · Sites in United States, Japan, Singapore
Ages 18+
Novartis Pharmaceuticals
Ages 18+
By country, each count listing its studies:
Of the 556 Hypertension studies recruiting now, 262 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 137 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
228 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 19 · Phase 2 31 · Phase 3 109 · Phase 4 67
First in 1989; this study’s year is marked. 25 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 818 is above the median of 100 across 4,585 interventional studies indexed under Hypertension.
Median enrollment 300 across the 223 interventional studies, 813 across the 4 observational. Of the 219 that completed or were terminated, 88 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
Novartis is the lead sponsor of 714 studies on the registry; none are open to participants now.
4 of the studies in Hypertension by Novartis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07644364Novartis PharmaceuticalsHJB647 Phase 1b Study in Japanese Healthy Participants With Elevated Blood Pressure and Patients With Hypertension | 2026-12-25 |
| NCT07610278Novartis PharmaceuticalsA Study to Evaluate the Pharmacodynamics of a Combination of QCZ484 and Inclisiran in Participants With Hypertension and Concomitant Hypercholesterolemia | 2027-04-28 |
| NCT07465666Novartis PharmaceuticalsA Real-world Study of the Effectiveness of Angiotensin Receptor-Neprilysin Inhibitor Therapy in Hypertensive Patients in the United Arab Emirates | 2027-08-31 |
| NCT07940647Novartis PharmaceuticalsA Safety and Tolerability Study of HJB647 in Adult Participants With Uncontrolled Hypertension | 2027-11-05 |
Add all 4 to your calendar (.ics) → With an account.
Among the 228 studies in Hypertension by Novartis, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will assess the safety and efficacy of combination aliskiren/amlodipine in patients not adequately controlled with aliskiren alone
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 1 Aliskiren/Amlodipine 300/5mg tablet + 1 Placebo to Aliskiren tablet once daily in the morning for 8 weeks.
Drug: Aliskiren/Amlodipine 300/5 mg · Drug: Placebo to Aliskiren
Participants received 1 Aliskiren/Amlodipine 300/10 mg tablet + 1 Placebo to Aliskiren tablet orally once daily in the morning for 8 weeks.
Drug: Aliskiren/Amlodipine 300/10 mg · Drug: Placebo to Aliskiren
Participants received 1 Aliskiren 300 mg tablet + 1 Placebo to Aliskiren/Amlodipine tablet orally once daily in the morning for 8 weeks.
Drug: Aliskiren 300 mg · Drug: Placebo to Aliskiren/Amlodipine
Aliskiren 300 mg tablet taken orally once a day with a glass of water.
Aliskiren/Amlodipine 300/5 mg tablet taken orally once a day with a glass of water.
Aliskiren/Amlodipine 300/10 mg taken orally once a day with a glass of water.
Placebo to Aliskiren tablet taken orally once a day.
Placebo to Aliskiren/Amlodipine taken orally once a day.
Change From Baseline to End of Study in the Mean Sitting Diastolic Blood Pressure (msDBP)
After the patient had been sitting for 5 minutes, systolic and diastolic blood pressures were measured 3 times using the automatic Blood Pressure monitor and appropriate size cuff. The repeat sitting measurements were made at 1-2 minute intervals and the mean of these 3 sitting blood pressure measurements was used as the average sitting blood pressure for that visit. The difference of the msDBP at baseline from the msDBP at 8 weeks was calculated using an Analysis of Covariance (ANCOVA) model with baseline as a covariate and treatment and region as two factors.
Time frame: Baseline, End of Study (Week 8)
Change From Baseline to End of Study in the Mean Sitting Systolic Blood Pressure (msSBP)
After the patient had been sitting for 5 minutes, systolic and diastolic blood pressures were measured 3 times using the automatic Blood Pressure monitor and appropriate size cuff. The repeat sitting measurements were made at 1-2 minute intervals and the mean of these 3 sitting blood pressure measurements was used as the average sitting blood pressure for that visit. The difference of the msSBP at baseline from the msSBP at 8 weeks was calculated using an ANCOVA model with baseline as a covariate and treatment and region as two factors.
Time frame: Baseline, End of Study (Week 8)
Number of Participants With Serious Adverse Events and Adverse Events
The number of participants with any Serious Adverse Event and the number of participants with Adverse Events in any system organ class. Additional information about Adverse Events can be found in the Adverse Event Section.
Time frame: 8 weeks
Percentage of Participants Achieving Blood Pressure Control
After the patient had been sitting for 5 minutes, with the back supported and both feet placed on the floor, systolic and diastolic blood pressures were measured 3 times using the automatic Blood Pressure monitor and appropriate size cuff. The repeat sitting measurements were made at 1-2 minute intervals and the mean of these 3 sitting blood pressure measurements was used as the average sitting blood pressure for that visit. Blood Pressure control was defined as having a mean sitting Diastolic Blood Pressure \<90 and a mean sitting Systolic Blood Pressure \<140.
Time frame: 8 weeks
Percentage of Participants Achieving a Diastolic Blood Pressure Response
After the patient had been sitting for 5 minutes, with the back supported and both feet placed on the floor, systolic and diastolic blood pressures were measured 3 times using the automatic Blood Pressure monitor and appropriate size cuff. The repeat sitting measurements were made at 1-2 minute intervals and the mean of these 3 sitting blood pressure measurements was used as the average sitting blood pressure for that visit. A Diastolic Blood Pressure Response was defined as a mean sitting Diastolic Blood Pressure (msDBP) \<90 mmHg or a ≥ 10 mmHg reduction in msDBP from baseline.
Time frame: 8 weeks
Percentage of Participants Achieving a Systolic Blood Pressure Response
After the patient had been sitting for 5 minutes, with the back supported and both feet placed on the floor, systolic and diastolic blood pressures were measured 3 times using the automatic Blood Pressure monitor and appropriate size cuff. The repeat sitting measurements were made at 1-2 minute intervals and the mean of these 3 sitting blood pressure measurements was used as the average sitting blood pressure for that visit. A Systolic Blood Pressure Response was defined as a mean sitting Systolic Blood Pressure (msSBP) \<140 mmHg or a ≥ 20 mmHg reduction in msSBP from baseline.
Time frame: 8 weeks
| Milestone | Aliskiren 300 mg/Amlodipine 10 mg | Aliskiren 300 mg/Amlodipine 5 mg | Aliskiren 300 mg |
|---|---|---|---|
| Started | 283 | 277 | 260 |
| Safety & full analysis sets | 282 | 276 | 260 |
| Completed | 262 | 271 | 244 |
| Not completed | 21 | 6 | 16 |
| Withdrew: Adverse event | 11 | 1 | 3 |
| Withdrew: Lack of efficacy | 0 | 0 | 9 |
| Withdrew: Condition no longer required study drug | 1 | 0 | 0 |
| Withdrew: Patient withdrew consent | 3 | 2 | 3 |
| Withdrew: Lost to follow-up | 3 | 1 | 0 |
| Withdrew: Protocol deviation | 2 | 1 | 1 |
| Withdrew: Randomized in error | 1 | 1 | 0 |
After the patient had been sitting for 5 minutes, systolic and diastolic blood pressures were measured 3 times using the automatic Blood Pressure monitor and appropriate size cuff. The repeat sitting measurements were made at 1-2 minute intervals and the mean of these 3 sitting blood pressure measurements was used as the average sitting blood pressure for that visit. The difference of the msDBP at baseline from the msDBP at 8 weeks was calculated using an Analysis of Covariance (ANCOVA) model with baseline as a covariate and treatment and region as two factors.
| mm Hg | Aliskiren 300 mg/Amlodipine 10 mg | Aliskiren 300 mg/Amlodipine 5 mg | Aliskiren 300 mg |
|---|---|---|---|
| Change From Baseline to End of Study in the Mean Sitting Diastolic Blood Pressure (msDBP) | -13.07 ± 0.463 | -10.54 ± 0.467 | -5.84 ± 0.480 |
After the patient had been sitting for 5 minutes, systolic and diastolic blood pressures were measured 3 times using the automatic Blood Pressure monitor and appropriate size cuff. The repeat sitting measurements were made at 1-2 minute intervals and the mean of these 3 sitting blood pressure measurements was used as the average sitting blood pressure for that visit. The difference of the msSBP at baseline from the msSBP at 8 weeks was calculated using an ANCOVA model with baseline as a covariate and treatment and region as two factors.
| mm Hg | Aliskiren 300 mg/Amlodipine 10 mg | Aliskiren 300 mg/Amlodipine 5 mg | Aliskiren 300 mg |
|---|---|---|---|
| Change From Baseline to End of Study in the Mean Sitting Systolic Blood Pressure (msSBP) | -18.04 ± 0.780 | -14.43 ± 0.788 | -6.42 ± 0.809 |
The number of participants with any Serious Adverse Event and the number of participants with Adverse Events in any system organ class. Additional information about Adverse Events can be found in the Adverse Event Section.
| participants | Aliskiren 300 mg/Amlodipine 10 mg | Aliskiren 300 mg/Amlodipine 5 mg | Aliskiren 300 mg |
|---|---|---|---|
| Serious Adverse Events | 3 | 4 | 1 |
| Adverse Events | 85 | 80 | 59 |
After the patient had been sitting for 5 minutes, with the back supported and both feet placed on the floor, systolic and diastolic blood pressures were measured 3 times using the automatic Blood Pressure monitor and appropriate size cuff. The repeat sitting measurements were made at 1-2 minute intervals and the mean of these 3 sitting blood pressure measurements was used as the average sitting blood pressure for that visit. Blood Pressure control was defined as having a mean sitting Diastolic Blood Pressure \<90 and a mean sitting Systolic Blood Pressure \<140.
| Percentage of participants | Aliskiren 300 mg/Amlodipine 10 mg | Aliskiren 300 mg/Amlodipine 5 mg | Aliskiren 300 mg |
|---|---|---|---|
| Percentage of Participants Achieving Blood Pressure Control | 65.5 | 56.5 | 31.5 |
After the patient had been sitting for 5 minutes, with the back supported and both feet placed on the floor, systolic and diastolic blood pressures were measured 3 times using the automatic Blood Pressure monitor and appropriate size cuff. The repeat sitting measurements were made at 1-2 minute intervals and the mean of these 3 sitting blood pressure measurements was used as the average sitting blood pressure for that visit. A Diastolic Blood Pressure Response was defined as a mean sitting Diastolic Blood Pressure (msDBP) \<90 mmHg or a ≥ 10 mmHg reduction in msDBP from baseline.
| Percentage of participants | Aliskiren 300 mg/Amlodipine 10 mg | Aliskiren 300 mg/Amlodipine 5 mg | Aliskiren 300 mg |
|---|---|---|---|
| Percentage of Participants Achieving a Diastolic Blood Pressure Response | 83.6 | 77.7 | 51.5 |
After the patient had been sitting for 5 minutes, with the back supported and both feet placed on the floor, systolic and diastolic blood pressures were measured 3 times using the automatic Blood Pressure monitor and appropriate size cuff. The repeat sitting measurements were made at 1-2 minute intervals and the mean of these 3 sitting blood pressure measurements was used as the average sitting blood pressure for that visit. A Systolic Blood Pressure Response was defined as a mean sitting Systolic Blood Pressure (msSBP) \<140 mmHg or a ≥ 20 mmHg reduction in msSBP from baseline.
| Percentage of participants | Aliskiren 300 mg/Amlodipine 10 mg | Aliskiren 300 mg/Amlodipine 5 mg | Aliskiren 300 mg |
|---|---|---|---|
| Percentage of Participants Achieving a Systolic Blood Pressure Response | 77.2 | 69.7 | 43.8 |
Collected over 8 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Aliskiren 300 mg/Amlodipine 10 mg | — | 3/282 (1.1%) | 26/282 (9.2%) |
| Aliskiren 300 mg/Amlodipine 5 mg | — | 4/276 (1.4%) | 6/276 (2.2%) |
| Aliskiren 300 mg | — | 1/260 (0.4%) | 1/260 (0.4%) |
| Event | Aliskiren 300 mg/Amlodipine 10 mg | Aliskiren 300 mg/Amlodipine 5 mg | Aliskiren 300 mg |
|---|---|---|---|
| Post-traumatic painInjury, poisoning and procedural complications | 0/282 | 0/276 | 1/260 |
| Road traffic accidentInjury, poisoning and procedural complications | 0/282 | 0/276 | 1/260 |
| VertigoEar and labyrinth disorders | 0/282 | 1/276 | 0/260 |
| PyrexiaGeneral disorders | 0/282 | 1/276 | 0/260 |
| Viral infectionInfections and infestations | 0/282 | 1/276 | 0/260 |
| Lung neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/282 | 1/276 | 0/260 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 0/282 | 1/276 | 0/260 |
| Drug hypersensitivityImmune system disorders | 1/282 | 0/276 | 0/260 |
| Lobar pneumoniaInfections and infestations | 1/282 | 0/276 | 0/260 |
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 1/282 | 0/276 | 0/260 |
| Event | Aliskiren 300 mg/Amlodipine 10 mg | Aliskiren 300 mg/Amlodipine 5 mg | Aliskiren 300 mg |
|---|---|---|---|
| Oedema peripheralGeneral disorders | 26/282 | 6/276 | 1/260 |
| Age Continuous(years) | Aliskiren 300 mg/Amlodipine 10 mg | Aliskiren 300 mg/Amlodipine 5 mg | Aliskiren 300 mg | Total |
|---|---|---|---|---|
| Mean | 54.6 ± 10.67 | 54.4 ± 10.69 | 54.7 ± 10.99 | 54.6 ± 10.77 |
| Sex: Female, Male(Participants) | Aliskiren 300 mg/Amlodipine 10 mg | Aliskiren 300 mg/Amlodipine 5 mg | Aliskiren 300 mg | Total |
|---|---|---|---|---|
| Female | 120 | 101 | 103 | 324 |
| Male | 163 | 176 | 157 | 496 |
The record gives a start of Oct 2008, a primary completion of May 2009 and a completion of May 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2011, 2 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.